James C D, He J, Carlbom E, Nordenskjold M, Cavenee W K, Collins V P
Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202.
Cancer Res. 1991 Mar 15;51(6):1684-8.
We have applied restriction fragment length polymorphism analysis to a 30-member panel of primary glioma DNAs, which had been previously examined for loss of genetic information (C. D. James, E. Carlbom, J. P. Dumanski, M. Hansen, M. Nordenskjold, V. P. Collins, and W. K. Cavenee, Cancer Res., 48:5546-5551, 1988), to determine the frequency and sublocalization of loss of genetic information from chromosome 9. We have also utilized scanning densitometry for dosage determination of the 9p-localized interferon alpha and interferon beta-1 genes among these same tumors. Our results reveal the following: (a) for those cases in which loss has occurred, the region of common loss lies on the short (p) arm of the chromosome; (b) loss of genetic information from the short arm of chromosome 9 occurs frequently in glial tumors of intermediate (anaplastic, grade III) and high (glioblastoma, grade IV) histological malignancy (10 of 20 cases) but not in tumors of low (grade II) histological malignancy (0 of 10 cases); (c) tumors with 9p deletions are hemi- or nullizygous for interferon beta-1 and the interferon alpha gene cluster; (d) cases of interferon nullizygosity occur exclusively among tumors of highest histological malignancy (glioblastoma). These data, especially the determination of a region of nullizygosity, suggest proximity to or residence within a gene(s) whose function(s) is (are) critical to the suppression of the malignant evolution of glial tumors.
我们已将限制性片段长度多态性分析应用于一个由30个原发性胶质瘤DNA组成的样本组,这些样本此前已检测过遗传信息的缺失情况(C.D.詹姆斯、E.卡尔博姆、J.P.杜曼斯基、M.汉森、M.诺登斯科尔德、V.P.柯林斯和W.K.卡文尼,《癌症研究》,48:5546 - 5551,1988),以确定9号染色体遗传信息缺失的频率和亚定位。我们还利用扫描密度计对这些相同肿瘤中位于9p的干扰素α和干扰素β - 1基因进行剂量测定。我们的结果显示如下:(a) 对于那些发生缺失的病例,共同缺失区域位于染色体的短(p)臂上;(b) 9号染色体短臂遗传信息的缺失在组织学恶性程度为中度(间变性,III级)和高度(胶质母细胞瘤,IV级)的胶质瘤中频繁发生(20例中有10例),但在组织学恶性程度低(II级)的肿瘤中未发生(10例中有0例);(c) 具有9p缺失的肿瘤对于干扰素β - 1和干扰素α基因簇是半合子或纯合子缺失;(d) 干扰素纯合子缺失的病例仅发生在组织学恶性程度最高的肿瘤(胶质母细胞瘤)中。这些数据,特别是纯合子缺失区域的确定,表明该区域靠近或存在一个基因,其功能对于抑制胶质瘤的恶性进展至关重要。